You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
報道指康希諾生物(06185.HK)擬啟動新型肺炎疫苗三期試驗
阿思達克 07-13 12:11
《路透》引述消息指,康希諾生物(06185.HK)執行董事兼聯合創始人邱東旭日前於一論壇上透露,公司正與俄羅斯、巴西、智利及沙特阿拉伯進行談判,以啟動其新型肺炎病毒實驗疫苗的三期試驗。

邱東旭表示,相關試驗可能很快開始,計劃招募4萬名參與者進行試驗,同時透露公司於中國在建的新工廠至2021年初每年可生產1億至2億劑新型肺炎病毒疫苗。

康希諾生物中午收報250元,升10.9%,成交204.6萬股,涉資4.97億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account